After signing up, you'll start to receive regular news updates from us.
Immunovaccine Appoints Wayne Pisano to its Board
Complete the form below to unlock access to ALL audio articles.
Immunovaccine Inc. has announced that Wayne Pisano, former president and chief executive officer of Sanofi Pasteur, has joined the Company's board of directors.
Immunovaccine develops new vaccines for cancer and infectious diseases delivered via its patented lipid-based technology.
"During his 14-year career at Sanofi, Mr. Pisano played a significant role in making the company into the global leader that it is today," said Albert Scardino, chairman of Immunovaccine.
Scardino continued, "His acceptance of this role with us is a testament to the strength of our science and to the quality of the management team and board we have assembled.
"He joins our new chief executive, John Trizzino, and our earlier appointment of Brad Thompson, of Oncolytics, to give us a strong management and board structure as we continue to advance multiple vaccine candidates based on our DepoVax™ platform."
Mr. Pisano retired from Sanofi Pasteur, the world's largest human vaccine company, in February of this year. With more than 30 years of experience in the pharmaceutical industry, he was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress.
His experience spans the spectrum of commercial operations, public immunization policies and pipeline development. He is widely recognized in the industry as having driven Sanofi Pasteur's success in the worldwide influenza market, capturing 40 percent of global sales. He also laid the foundation for the company's global pediatric vaccines strategy.
He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. As senior vice president of global operations, he increased revenues to more than 2 billion euros for the first time in the company's history.
Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.
"This is an exciting time to join such a promising vaccine development company," Mr. Pisano said.
Mr. Pisano continued, "With opportunities to leverage its platform technology, DepoVax, in other vaccine candidates and with a second therapeutic cancer vaccine, DPX-Survivac, moving into a Phase I trial, I trust my background in strategy development, in-licensing, and global acquisitions will be helpful."
